Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target

Por Lepak, A., Marchillo, K., VanHecker, J., Andes, D.
Publicado no Antimicrob Agents Chemother (2015)

Time Course of Microbiologic Outcome and Gene Expression in Candida albicans during and following In Vitro and In Vivo Exposure to Fluconazole

Por Lepak, A., Nett, J., Lincoln, L., Marchillo, K., Andes, D.
Publicado em 2006

In Vivo Fluconazole Pharmacodynamics and Resistance Development in a Previously Susceptible Candida albicans Population Examined by Microbiologic and Transcriptional Profiling

Por Andes, D., Lepak, A., Nett, J., Lincoln, L., Marchillo, K.
Publicado em 2006

Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice

Por Lepak, A., Marchillo, K., VanHecker, J., Azie, N., Andes, D.
Publicado no Antimicrob Agents Chemother (2015)

Impact of Antimicrobial Dosing Regimen on Evolution of Drug Resistance In Vivo: Fluconazole and Candida albicans

Por Andes, D., Forrest, A., Lepak, A., Nett, J., Marchillo, K., Lincoln, L.
Publicado em 2006

In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species

Por Andes, D., Diekema, D. J., Pfaller, M. A., Bohrmuller, J., Marchillo, K., Lepak, A.
Publicado em 2010

Impact of MIC Range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the Ceftolozane In Vivo Pharmacokinetic/Pharmacodynamic Target

Por Lepak, A. J., Reda, A., Marchillo, K., Van Hecker, J., Craig, W. A., Andes, D.
Publicado em 2014

In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneum...

Por Lepak, A. J., Seiler, P., Surivet, J. P., Ritz, D., Kohl, C., Andes, D. R.
Publicado no Antimicrob Agents Chemother (2016)